Searchable abstracts of presentations at key conferences in endocrinology

ea0029p815 | Endocrine tumours and neoplasia | ICEECE2012

Differential TNFα -synthesis and signaling in endocrine tumors after treatment with the Tumor-Vascular-Disrupting Agent ASA404 (vadimezan)

Hantel C. , Ozimek A. , Frantsev R. , Scheller F. , Reincke M. , Mussack T. , Beuschlein F.

Recently, we investigated effects of the Tumor-VDA ASA404 in tumor models for neuroendocrine tumors of the gastroenteropancreatic system and adrenocortical carcinoma 24 hours after treatment of BON and NCIh295 tumor bearing mice with ASA404 (A), paclitaxel (P) or the combination (A+P). We detected for BON tumors extensive necrotic areas as well as a significant decrease in cell proliferation, increase of apoptotic cells and reduction of microvessels after A or A+P treatment wh...

ea0026p60 | Endocrine tumours and neoplasia | ECE2011

Development and characterisation of patient-individual tumor models for endocrine tumors

Hantel C , Scheller F , Ozimek A , Chiapponi C , Mussack T , Beuschlein F

Only a few cell lines are available for endocrine tumors which furthermore do not reflect heterogenous functional properties and specific therapeutic response rates of individual tumors. To facilitate patient individual treatments and thereby to optimize therapeutic efficacy, we are aiming at the development and characterisation of patient-individual tumor models. Pieces of surgical tumor specimen from four adrenocortical carcinomas, one aldosterone producing adenoma, one pheo...